$IPSC

Russotti Gregory sold $6K of IPSC

Russotti Gregory (See Remarks) sold 2,584 shares of Century Therapeutics, Inc. (IPSC) at $2.23 on 2026-06-12.

Original reporting
SEC EDGAR · Russotti Gregory
Published Jun 15, 2026, 11:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 11:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IPSC
Neutral
medium confidence
Mentioned
$IPSC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

An officer/direct insider sold shares in an open-market transaction; without additional company news, the trading implication is mainly sentiment/positioning rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article lacks context on total insider holdings, prior sale cadence, and whether other insiders/10b5-1 plans are active—these can materially change interpretation.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-15 for a 2026-06-12 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Century Therapeutics, Inc.

Company-level read

Ticker impact

$IPSCNeutralMedium confidence
Context

SEC Form 4 shows officer Russotti Gregory sold 2,584 shares of Century Therapeutics (IPSC) on 2026-06-12 at $2.2320.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless accompanied by other disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but it is a small, single-sale event with no accompanying operational/regulatory catalyst in the text.

Market effects

No sector read-through provided; this is company-specific ownership activity only.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; absence of a 10b5-1 plan doesn’t necessarily imply negative fundamentals.

Key entities

  • Century Therapeutics, Inc.

    Subject of the SEC Form 4 insider transaction disclosure (IPSC).

  • Russotti Gregory

    Officer who executed the open-market sale of 2,584 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IPSCHighAI 8/10

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

$IPSCMed

Century Therapeutics, Inc. (IPSC): Results of Operations and Financial Condition

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

$IPSCMedAI 8/10

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa